• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    Orexigen Therapeutics, Inc. (OREX)

    0.42 Up 0.01(1.68%) May 27, 4:00PM EDT
    |After Hours : 0.43 Up 0.01 (2.90%) May 27, 6:01PM EDT
    ProfileGet Profile for:
    Orexigen Therapeutics, Inc.
    3344 North Torrey Pines Court
    Suite 200
    La Jolla, CA 92037
    United States - Map
    Phone: 858-875-8600
    Fax: 858-875-8650
    Website: http://www.orexigen.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Other
    Full Time Employees:67

    Business Summary 

    Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in the United States, Canada, and Mexico. The company’s product, Contrave also approved under the brand name of Mysimba in Europe. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Orexigen Therapeutics, Inc.

    Corporate Governance 
    Orexigen Therapeutics, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 5; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Michael A. Narachi M.S., M.B.A., 57
    Chief Exec. Officer, Pres, Interim Chief Financial Officer and Director
    Mr. Thomas P. Lynch ,
    Exec. VP, Gen. Counsel and Sec.
    Dr. Thomas R. Cannell DVM, 54
    Chief Commercial Officer and Exec. VP
    Mr. Joseph P. Hagan , 47
    Stephen A. Moglia ,
    Chief Accounting Officer, VP and Controller
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders